BEAM

Beam Therapeutics Inc

Add to Watchlist

Advanced Chart

18.830

-0.88(-4.465%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

19.410

Open

19.275

VWAP

19.07

Vol

2.71M

Mkt Cap

1.89B

Low

18.645

Amount

51.73M

EV/EBITDA(TTM)

Total Shares

82.31M

762.03M

EV/OCF(TTM)

P/S(TTM)

26.00

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

18.74M

-37.68%

-1.068

-2.01%

14.58M

+2.16%

-1.094

-6.54%

13.29M

+12.91%

-1.091

-1.69%

Estimates Revision

The market is revising Downward the revenue expectations for Beam Therapeutics Inc. (BEAM) for FY2025, with the revenue forecasts being adjusted by -13.01% over the past three months. During the same period, the stock price has changed by -5.04%.

Revenue Estimates for FY2025

Revise Downward

-13.01%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-3.47%

In Past 3 Month

Stock Price

Go Down

-5.04%

In Past 3 Month

13 Analyst Rating

138.98% Upside

Wall Street analysts forecast BEAM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BEAM is 45.00 USD with a low forecast of 20.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

2 Hold

0 Sell

Strong Buy

138.98% Upside

Current: 18.830

Low

20.00

Averages

45.00

High

80.00

138.98% Upside

Current: 18.830

Low

20.00

Averages

45.00

High

80.00

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$80

2025-04-07

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$80

2025-04-07

Reiterates

Strong Buy

Reason

B of A Securities

Alec Stranahan

Hold

Strong Buy

Upgrades

$42

2025-03-28

Reason

B of A Securities

Alec Stranahan

Price Target

$42

2025-03-28

Upgrades

Hold

Strong Buy

Reason

Cantor Fitzgerald

Rick Bienkowski

Buy

Reiterates

n/a

2025-03-12

Reason

Cantor Fitzgerald

Rick Bienkowski

Price Target

n/a

2025-03-12

Reiterates

Buy

Reason

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$80

2025-03-10

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$80

2025-03-10

Reiterates

Strong Buy

Reason

Jones Trading

Soumit Roy

Hold

Strong Buy

Upgrades

$34

2025-03-10

Reason

Jones Trading

Soumit Roy

Price Target

$34

2025-03-10

Upgrades

Hold

Strong Buy

Reason

JonesResearch upgraded Beam Therapeutics to Buy from Hold with a $34 price target.

Scotiabank

Greg Harrison

Hold

Buy

Upgrades

$40

2025-03-10

Reason

Scotiabank

Greg Harrison

Price Target

$40

2025-03-10

Upgrades

Hold

Buy

Reason

Scotiabank raised the firm's price target on Beam Therapeutics to $25 from $24 and keeps a Sector Perform rating on the shares. The firm likes the company's setup for the rest of the year, but remains cautious until more clinical derisking occurs, the analyst tells investors.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Beam Therapeutics Inc (BEAM.O) is -4.64, compared to its 5-year average forward P/E of -11.25. For a more detailed relative valuation and DCF analysis to assess Beam Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-11.25

Current PE

-4.64

Overvalued PE

-3.39

Undervalued PE

-19.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-9.17

Current EV/EBITDA

-1.95

Overvalued EV/EBITDA

0.27

Undervalued EV/EBITDA

-18.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

6041.58

Current PS

30.79

Overvalued PS

37896.31

Undervalued PS

-25813.15

Financials

Annual

Quarterly

FY2025Q1

YoY :

+0.81%

7.47M

Total Revenue

FY2025Q1

YoY :

+14.55%

-119.29M

Operating Profit

FY2025Q1

YoY :

+10.74%

-109.27M

Net Income after Tax

FY2025Q1

YoY :

+2.48%

-1.24

EPS - Diluted

FY2025Q1

YoY :

+4.66%

-106.95M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

+1110.53%

-567.74

FCF Margin - %

FY2025Q1

YoY :

+9.85%

-1.46K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

1.0M

USD

3-6

Months

1.4M

USD

6-9

Months

860.7K

USD

0-12

Months

2.8M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 161.22% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

377.0K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

2.4M

Volume

Months

6-9

929.1K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

1.0M

USD

3-6

Months

1.4M

USD

6-9

Months

860.7K

USD

0-12

Months

2.8M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

BEAM News & Events

Events Timeline

2025-06-13 (ET)

2025-06-13

07:01:45

Beam Therapeutics announces new data from BEACON Phase 1/2 trial

2025-06-03 (ET)

2025-06-03

07:04:59

Beam Therapeutics announces U.S. FDA granted ODD to BEAM-101

2025-05-30 (ET)

2025-05-30

14:57:01

Beam Therapeutics treatment of sickle cell disease granted orphan designation

News

4.0

07-28TipRanks

Analysts Spot 3 Strong Buy Russell 2000 Stocks with 100% Upside

5.0

07-08TipRanks

Cathie Wood Starts This Volatile Week with $13M Buy and a Key Sell-Off

4.0

07-06Yahoo Finance

H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT

People Also Watch

FAQ

What is Beam Therapeutics Inc (BEAM) stock price today?

The current price of BEAM is 18.83 USD — it has decreased -4.46 % in the last trading day.

BEAM

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

BEAM News & Events

Events Timeline

News

People Also Watch

FAQ

What is Beam Therapeutics Inc (BEAM) stock price today?

What is Beam Therapeutics Inc (BEAM)'s business?

What is the price predicton of BEAM Stock?

What is Beam Therapeutics Inc (BEAM)'s revenue for the last quarter?

What is Beam Therapeutics Inc (BEAM)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Beam Therapeutics Inc (BEAM)'s fundamentals?

How many employees does Beam Therapeutics Inc (BEAM). have?

What is Beam Therapeutics Inc (BEAM) market cap?